Enhancing Adoptive Cell Therapy of Cancer through Targeted Delivery of Small-Molecule Immunomodulators to Internalizing or Noninternalizing Receptors

ACS Nano

Volumn 11, Issue 3, 2017, Pages 3089-3100

  Zheng, Yiran ^a,b   Tang, Li ^b   Mabardi, Llian ^b   Kumari, Sudha ^b   Irvine, Darrell J ^a,b,c,d  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c HARVARD UNIVERSITY   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

adoptive cell therapy; cancer immunotherapy; immunoliposomes; melanoma; targeted delivery; TGF receptor inhibitor

Indexed keywords

CONTROLLED DRUG DELIVERY; CYTOLOGY; DISEASES; DRUG DOSAGE; DRUG PRODUCTS; LIPOSOMES; MOLECULES; TARGETED DRUG DELIVERY; TUMORS;

ADOPTIVE CELL THERAPY; CANCER IMMUNOTHERAPY; CELL THERAPY; IMMUNOLIPOSOMES; IN-VITRO; IN-VIVO; MELANOMA; TARGETED DELIVERY; TRANSFORMING GROWTH FACTOR-Β RECEPTOR INHIBITOR; TRANSFORMING GROWTH FACTORS;

T-CELLS;

IMMUNOLOGIC FACTOR; PTPRC PROTEIN, MOUSE; RECEPTOR TYPE TYROSINE PROTEIN PHOSPHATASE C; THY 1 MEMBRANE GLYCOPROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ADOPTIVE IMMUNOTHERAPY; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECT; EXPERIMENTAL MELANOMA; FEMALE; IMMUNOLOGY; METABOLISM; MOLECULAR LIBRARY; MOUSE; PATHOLOGY; PHARMACOLOGY; T LYMPHOCYTE; TRANSPLANTATION;

ANIMALS; DRUG DELIVERY SYSTEMS; FEMALE; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY, ADOPTIVE; LEUKOCYTE COMMON ANTIGENS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; SMALL MOLECULE LIBRARIES; T-LYMPHOCYTES; THY-1 ANTIGENS; TRANSFORMING GROWTH FACTOR BETA;

EID: 85016431555     PISSN: 19360851     EISSN: 1936086X     Source Type: Journal    
DOI: 10.1021/acsnano.7b00078     Document Type: Article

References (54)

1. Klebanoff, C. A.; Rosenberg, S. A.; Restifo, N. P. Prospects for Gene-Engineered T Cell Immunotherapy for Solid Cancers Nat. Med. 2016, 22, 26-36 10.1038/nm.4015
2. Rosenberg, S. A.; Restifo, N. P. Adoptive Cell Transfer as Personalized Immunotherapy for Human Cancer Science 2015, 348, 62-68 10.1126/science.aaa4967
3. Maus, M. V.; Fraietta, J. A.; Levine, B. L.; Kalos, M.; Zhao, Y.; June, C. H. Adoptive Immunotherapy for Cancer or Viruses Annu. Rev. Immunol. 2014, 32, 189-225 10.1146/annurev-immunol-032713-120136
4. Maude, S. L.; Frey, N.; Shaw, P. A.; Aplenc, R.; Barrett, D. M.; Bunin, N. J.; Chew, A.; Gonzalez, V. E.; Zheng, Z.; Lacey, S. F.; Mahnke, Y. D.; Melenhorst, J. J.; Rheingold, S. R.; Shen, A.; Teachey, D. T.; Levine, B. L.; June, C. H.; Porter, D. L.; Grupp, S. A. Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia N. Engl. J. Med. 2014, 371, 1507-1517 10.1056/NEJMoa1407222
5. Kalos, M.; Levine, B. L.; Porter, D. L.; Katz, S.; Grupp, S. A.; Bagg, A.; June, C. H. T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia Sci. Transl. Med. 2011, 3, 95ra73 10.1126/scitranslmed.3002842
6. Restifo, N. P.; Dudley, M. E.; Rosenberg, S. A. Adoptive Immunotherapy for Cancer: Harnessing the T Cell Response Nat. Rev. Immunol. 2012, 12, 269-281 10.1038/nri3191
7. Rosenberg, S. A.; Yang, J. C.; Sherry, R. M.; Kammula, U. S.; Hughes, M. S.; Phan, G. Q.; Citrin, D. E.; Restifo, N. P.; Robbins, P. F.; Wunderlich, J. R.; Morton, K. E.; Laurencot, C. M.; Steinberg, S. M.; White, D. E.; Dudley, M. E. Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy Clin. Cancer Res. 2011, 17, 4550-4557 10.1158/1078-0432.CCR-11-0116
8. Yee, C.; Thompson, J. A.; Byrd, D.; Riddell, S. R.; Roche, P.; Celis, E.; Greenberg, P. D. Adoptive T Cell Therapy Using Antigen-Specific Cd8+ T Cell Clones for the Treatment of Patients with Metastatic Melanoma: In Vivo Persistence, Migration, and Antitumor Effect of Transferred T Cells Proc. Natl. Acad. Sci. U. S. A. 2002, 99, 16168-16173 10.1073/pnas.242600099
9. Morgan, R. A.; Dudley, M. E.; Wunderlich, J. R.; Hughes, M. S.; Yang, J. C.; Sherry, R. M.; Royal, R. E.; Topalian, S. L.; Kammula, U. S.; Restifo, N. P.; Zheng, Z.; Nahvi, A.; de Vries, C. R.; Rogers-Freezer, L. J.; Mavroukakis, S. A.; Rosenberg, S. A. Cancer Regression in Patients after Transfer of Genetically Engineered Lymphocytes Science 2006, 314, 126-129 10.1126/science.1129003
10. June, C. H. Principles of Adoptive T Cell Cancer Therapy J. Clin. Invest. 2007, 117, 1204-1212 10.1172/JCI31446
11. Kalos, M.; June, C. H. Adoptive T Cell Transfer for Cancer Immunotherapy in the Era of Synthetic Biology Immunity 2013, 39, 49-60 10.1016/j.immuni.2013.07.002
12. Rabinovich, G. A.; Gabrilovich, D.; Sotomayor, E. M. Immunosuppressive Strategies That Are Mediated by Tumor Cells Annu. Rev. Immunol. 2007, 25, 267-296 10.1146/annurev.immunol.25.022106.141609
13. Akhurst, R. J.; Hata, A. Targeting the Tgfbeta Signalling Pathway in Disease Nat. Rev. Drug Discovery 2012, 11, 790-811 10.1038/nrd3810
14. Yang, L.; Pang, Y.; Moses, H. L. Tgf-Beta and Immune Cells: An Important Regulatory Axis in the Tumor Microenvironment and Progression Trends Immunol. 2010, 31, 220-227 10.1016/j.it.2010.04.002
15. Kehrl, J. H.; Wakefield, L. M.; Roberts, A. B.; Jakowlew, S.; Alvarez-Mon, M.; Derynck, R.; Sporn, M. B.; Fauci, A. S. Production of Transforming Growth Factor Beta by Human T Lymphocytes and Its Potential Role in the Regulation of T Cell Growth J. Exp. Med. 1986, 163, 1037-1050 10.1084/jem.163.5.1037
16. Wrzesinski, S. H.; Wan, Y. Y.; Flavell, R. A. Transforming Growth Factor-Beta and the Immune Response: Implications for Anticancer Therapy Clin. Cancer Res. 2007, 13, 5262-5270 10.1158/1078-0432.CCR-07-1157
17. Thomas, D. A.; Massague, J. Tgf-Beta Directly Targets Cytotoxic T Cell Functions During Tumor Evasion of Immune Surveillance Cancer Cell 2005, 8, 369-380 10.1016/j.ccr.2005.10.012
18. Ahmadzadeh, M.; Rosenberg, S. A. Tgf-Beta 1 Attenuates the Acquisition and Expression of Effector Function by Tumor Antigen-Specific Human Memory Cd8 T Cells J. Immunol. 2005, 174, 5215-5223 10.4049/jimmunol.174.9.5215
19. Stephen, T. L.; Rutkowski, M. R.; Allegrezza, M. J.; Perales-Puchalt, A.; Tesone, A. J.; Svoronos, N.; Nguyen, J. M.; Sarmin, F.; Borowsky, M. E.; Tchou, J.; Conejo-Garcia, J. R. Transforming Growth Factor Beta-Mediated Suppression of Antitumor T Cells Requires Foxp1 Transcription Factor Expression Immunity 2014, 41, 427-439 10.1016/j.immuni.2014.08.012
20. Donkor, M. K.; Sarkar, A.; Savage, P. A.; Franklin, R. A.; Johnson, L. K.; Jungbluth, A. A.; Allison, J. P.; Li, M. O. T Cell Surveillance of Oncogene-Induced Prostate Cancer Is Impeded by T Cell-Derived Tgf-Beta 1 Cytokine Immunity 2011, 35, 123-134 10.1016/j.immuni.2011.04.019
21. Li, M. O.; Wan, Y. Y.; Sanjabi, S.; Robertson, A. K.; Flavell, R. A. Transforming Growth Factor-Beta Regulation of Immune Responses Annu. Rev. Immunol. 2006, 24, 99-146 10.1146/annurev.immunol.24.021605.090737
22. Laouar, Y.; Sutterwala, F. S.; Gorelik, L.; Flavell, R. A. Transforming Growth Factor-Beta Controls T Helper Type 1 Cell Development through Regulation of Natural Killer Cell Interferon-Gamma Nat. Immunol. 2005, 6, 600-607 10.1038/ni1197
23. Gorelik, L.; Flavell, R. A. Immune-Mediated Eradication of Tumors through the Blockade of Transforming Growth Factor-Beta Signaling in T Cells Nat. Med. 2001, 7, 1118-1122 10.1038/nm1001-1118
24. Rowland-Goldsmith, M. A.; Maruyama, H.; Kusama, T.; Ralli, S.; Korc, M. Soluble Type Ii Transforming Growth Factor-Beta (Tgf-Beta) Receptor Inhibits Tgf-Beta Signaling in Colo-357 Pancreatic Cancer Cells in Vitro and Attenuates Tumor Formation Clin. Cancer Res. 2001, 7, 2931-2940
25. Zhang, Q.; Yang, X.; Pins, M.; Javonovic, B.; Kuzel, T.; Kim, S. J.; Parijs, L. V.; Greenberg, N. M.; Liu, V.; Guo, Y.; Lee, C. Adoptive Transfer of Tumor-Reactive Transforming Growth Factor-Beta-Insensitive Cd8+ T Cells: Eradication of Autologous Mouse Prostate Cancer Cancer Res. 2005, 65, 1761-1769 10.1158/0008-5472.CAN-04-3169
26. Tran, T. T.; Uhl, M.; Ma, J. Y.; Janssen, L.; Sriram, V.; Aulwurm, S.; Kerr, I.; Lam, A.; Webb, H. K.; Kapoun, A. M.; Kizer, D. E.; McEnroe, G.; Hart, B.; Axon, J.; Murphy, A.; Chakravarty, S.; Dugar, S.; Protter, A. A.; Higgins, L. S.; Wick, W. et al. Inhibiting Tgf-Beta Signaling Restores Immune Surveillance in the Sma-560 Glioma Model Neuro-Oncology 2007, 9, 259-270 10.1215/15228517-2007-010
27. Uhl, M.; Aulwurm, S.; Wischhusen, J.; Weiler, M.; Ma, J. Y.; Almirez, R.; Mangadu, R.; Liu, Y. W.; Platten, M.; Herrlinger, U.; Murphy, A.; Wong, D. H.; Wick, W.; Higgins, L. S.; Weller, M. Sd-208, a Novel Transforming Growth Factor Beta Receptor I Kinase Inhibitor, Inhibits Growth and Invasiveness and Enhances Immunogenicity of Murine and Human Glioma Cells in Vitro and in Vivo Cancer Res. 2004, 64, 7954-7961 10.1158/0008-5472.CAN-04-1013
28. Tanaka, H.; Shinto, O.; Yashiro, M.; Yamazoe, S.; Iwauchi, T.; Muguruma, K.; Kubo, N.; Ohira, M.; Hirakawa, K. Transforming Growth Factor Beta Signaling Inhibitor, Sb-431542, Induces Maturation of Dendritic Cells and Enhances Anti-Tumor Activity Oncol. Rep. 2010, 24, 1637-1643 10.3892/or-00001028
29. Bhola, N. E.; Balko, J. M.; Dugger, T. C.; Kuba, M. G.; Sanchez, V.; Sanders, M.; Stanford, J.; Cook, R. S.; Arteaga, C. L. Tgf-Beta Inhibition Enhances Chemotherapy Action against Triple-Negative Breast Cancer J. Clin. Invest. 2013, 123, 1348-1358 10.1172/JCI65416
30. Park, J.; Wrzesinski, S. H.; Stern, E.; Look, M.; Criscione, J.; Ragheb, R.; Jay, S. M.; Demento, S. L.; Agawu, A.; Licona Limon, P.; Ferrandino, A. F.; Gonzalez, D.; Habermann, A.; Flavell, R. A.; Fahmy, T. M. Combination Delivery of Tgf-Beta Inhibitor and Il-2 by Nanoscale Liposomal Polymeric Gels Enhances Tumour Immunotherapy Nat. Mater. 2012, 11, 895-905 10.1038/nmat3355
31. Garrison, K.; Hahn, T.; Lee, W. C.; Ling, L. E.; Weinberg, A. D.; Akporiaye, E. T. The Small Molecule Tgf-Beta Signaling Inhibitor Sm16 Synergizes with Agonistic Ox40 Antibody to Suppress Established Mammary Tumors and Reduce Spontaneous Metastasis Cancer Immunol. Immunother. 2012, 61, 511-521 10.1007/s00262-011-1119-y
32. Kano, M. R.; Bae, Y.; Iwata, C.; Morishita, Y.; Yashiro, M.; Oka, M.; Fujii, T.; Komuro, A.; Kiyono, K.; Kaminishi, M.; Hirakawa, K.; Ouchi, Y.; Nishiyama, N.; Kataoka, K.; Miyazono, K. Improvement of Cancer-Targeting Therapy, Using Nanocarriers for Intractable Solid Tumors by Inhibition of Tgf-Beta Signaling Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 3460-3465 10.1073/pnas.0611660104
33. Neuzillet, C.; Tijeras-Raballand, A.; Cohen, R.; Cros, J.; Faivre, S.; Raymond, E.; de Gramont, A. Targeting the Tgfbeta Pathway for Cancer Therapy Pharmacol. Ther. 2015, 147, 22-31 10.1016/j.pharmthera.2014.11.001
34. Rodon, J.; Carducci, M. A.; Sepulveda-Sanchez, J. M.; Azaro, A.; Calvo, E.; Seoane, J.; Brana, I.; Sicart, E.; Gueorguieva, I.; Cleverly, A. L.; Pillay, N. S.; Desaiah, D.; Estrem, S. T.; Paz-Ares, L.; Holdhoff, M.; Blakeley, J.; Lahn, M. M.; Baselga, J. First-in-Human Dose Study of the Novel Transforming Growth Factor-Beta Receptor I Kinase Inhibitor Ly2157299 Monohydrate in Patients with Advanced Cancer and Glioma Clin. Cancer Res. 2015, 21, 553-560 10.1158/1078-0432.CCR-14-1380
35. Herbertz, S.; Sawyer, J. S.; Stauber, A. J.; Gueorguieva, I.; Driscoll, K. E.; Estrem, S. T.; Cleverly, A. L.; Desaiah, D.; Guba, S. C.; Benhadji, K. A.; Slapak, C. A.; Lahn, M. M. Clinical Development of Galunisertib (Ly2157299 Monohydrate), a Small Molecule Inhibitor of Transforming Growth Factor-Beta Signaling Pathway Drug Des., Dev. Ther. 2015, 9, 4479-4499 10.2147/DDDT.S86621
36. Shull, M. M.; Ormsby, I.; Kier, A. B.; Pawlowski, S.; Diebold, R. J.; Yin, M.; Allen, R.; Sidman, C.; Proetzel, G.; Calvin, D.; Annunziata, N.; Doetschman, T. Targeted Disruption of the Mouse Transforming Growth Factor-Beta 1 Gene Results in Multifocal Inflammatory Disease Nature 1992, 359, 693-699 10.1038/359693a0
37. Aoki, C. A.; Borchers, A. T.; Li, M.; Flavell, R. A.; Bowlus, C. L.; Ansari, A. A.; Gershwin, M. E. Transforming Growth Factor Beta (Tgf-Beta) and Autoimmunity Autoimmun. Rev. 2005, 4, 450-459 10.1016/j.autrev.2005.03.006
38. Ohtsuka, K.; Gray, J. D.; Stimmler, M. M.; Toro, B.; Horwitz, D. A. Decreased Production of Tgf-Beta by Lymphocytes from Patients with Systemic Lupus Erythematosus J. Immunol. 1998, 160, 2539-2545
39. Holmdahl, R.; Bockermann, R.; Backlund, J.; Yamada, H. The Molecular Pathogenesis of Collagen-Induced Arthritis in Mice - a Model for Rheumatoid Arthritis Ageing Res. Rev. 2002, 1, 135-147 10.1016/S0047-6374(01)00371-2
40. Garber, K. Companies Waver in Efforts to Target Transforming Growth Factor Beta in Cancer J. Natl. Cancer Inst. 2009, 101, 1664-1667 10.1093/jnci/djp462
41. Anderton, M. J.; Mellor, H. R.; Bell, A.; Sadler, C.; Pass, M.; Powell, S.; Steele, S. J.; Roberts, R. R.; Heier, A. Induction of Heart Valve Lesions by Small-Molecule Alk5 Inhibitors Toxicol. Pathol. 2011, 39, 916-924 10.1177/0192623311416259
42. Xu, Z.; Wang, Y.; Zhang, L.; Huang, L. Nanoparticle-Delivered Transforming Growth Factor-Beta Sirna Enhances Vaccination against Advanced Melanoma by Modifying Tumor Microenvironment ACS Nano 2014, 8, 3636-3645 10.1021/nn500216y
43. Wilhelm, S.; Tavares, A. J.; Dai, Q.; Ohta, S.; Audet, J.; Dvorak, H. F.; Chan, W. C. W. Analysis of Nanoparticle Delivery to Tumours Nat. Rev. Mater. 2016, 1, 16014 10.1038/natrevmats.2016.14
44. Stephan, M. T.; Moon, J. J.; Um, S. H.; Bershteyn, A.; Irvine, D. J. Therapeutic Cell Engineering with Surface-Conjugated Synthetic Nanoparticles Nat. Med. 2010, 16, 1035-1041 10.1038/nm.2198
45. Stephan, M. T.; Stephan, S. B.; Bak, P.; Chen, J.; Irvine, D. J. Synapse-Directed Delivery of Immunomodulators Using T-Cell-Conjugated Nanoparticles Biomaterials 2012, 33, 5776-5787 10.1016/j.biomaterials.2012.04.029
46. Huang, B.; Abraham, W. D.; Zheng, Y.; Bustamante Lopez, S. C.; Luo, S. S.; Irvine, D. J. Active Targeting of Chemotherapy to Disseminated Tumors Using Nanoparticle-Carrying T Cells Sci. Transl. Med. 2015, 7, 291ra294 10.1126/scitranslmed.aaa5447
47. Zheng, Y.; Stephan, M. T.; Gai, S. A.; Abraham, W.; Shearer, A.; Irvine, D. J. In Vivo Targeting of Adoptively Transferred T-Cells with Antibody- and Cytokine-Conjugated Liposomes J. Controlled Release 2013, 172, 426-435 10.1016/j.jconrel.2013.05.037
48. Grygielko, E. T.; Martin, W. M.; Tweed, C.; Thornton, P.; Harling, J.; Brooks, D. P.; Laping, N. J. Inhibition of Gene Markers of Fibrosis with a Novel Inhibitor of Transforming Growth Factor-Beta Type I Receptor Kinase in Puromycin-Induced Nephritis J. Pharmacol. Exp. Ther. 2005, 313, 943-951 10.1124/jpet.104.082099
49. Cullen, S. P.; Brunet, M.; Martin, S. J. Granzymes in Cancer and Immunity Cell Death Differ. 2010, 17, 616-623 10.1038/cdd.2009.206
50. Allen, T. M. Ligand-Targeted Therapeutics in Anticancer Therapy Nat. Rev. Cancer 2002, 2, 750-763 10.1038/nrc903
51. Chen, S.; Zhao, X.; Chen, J.; Chen, J.; Kuznetsova, L.; Wong, S. S.; Ojima, I. Mechanism-Based Tumor-Targeting Drug Delivery System. Validation of Efficient Vitamin Receptor-Mediated Endocytosis and Drug Release Bioconjugate Chem. 2010, 21, 979-987 10.1021/bc9005656
52. Thomas, M. L. The Leukocyte Common Antigen Family Annu. Rev. Immunol. 1989, 7, 339-369 10.1146/annurev.immunol.7.1.339
53. Hermiston, M. L.; Xu, Z.; Weiss, A. Cd45: A Critical Regulator of Signaling Thresholds in Immune Cells Annu. Rev. Immunol. 2003, 21, 107-137 10.1146/annurev.immunol.21.120601.140946
54. Trowbridge, I. S.; Thomas, M. L. Cd45: An Emerging Role as a Protein Tyrosine Phosphatase Required for Lymphocyte Activation and Development Annu. Rev. Immunol. 1994, 12, 85-116 10.1146/annurev.iy.12.040194.000505